Parkinson's drug pump could smooth out daily 'Off' episodes

NCT ID NCT01883505

Completed Disease control Sponsor: NeuroDerm Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a new way to deliver levodopa—the main Parkinson's medication—through a continuous infusion under the skin. It is designed for people with Parkinson's who experience at least two hours of 'off' time each day, when symptoms return between oral doses. The trial will check safety, how the drug moves in the body, and whether it helps reduce those off periods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ND0612 (levodopa and carbidopa solution given as a continuous infusion under the skin)
What this could lead to: If it works, this could offer a more steady way to deliver levodopa, reducing the daily 'off' periods when Parkinson's symptoms return between doses.
What could go wrong: This is a small, early-phase study focused on safety and drug levels, not yet proven to improve symptoms. Side effects from the infusion or the drug itself are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE

Contacts and locations

Show contact details

Locations

Hadassah Medical Center

Jerusalem, Israel
Rabin Medical Center

Petah Tikva, Israel
Tel Aviv Medical Center

Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.